• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [22292 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Examination and treatment of older people after a fall – a health technology assessment]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Examination of barriers and facilitators for the implementation of clinical practice guidelines: a Delphi study]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Exantia® tissue bulking agent for the treatment of fecal incontinence]
2020     National Committee for Technology Incorporation (CONITEC) [Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exenatide in diabetes mellitus type 2 - Rapid report]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Exercise therapy (Krankengymnastik / Heilgymnastik) in physical medicine]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy for patellofemoral pain syndrome: a randomised clinical trial in general practice and sports medicine]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy in patients with peripheral arterial disease: the costs and effectiveness of physiotherapeutic supervision with or without therapy feedback versus a 'go home and walk' advice]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Expanding thrombolysis in acute ischemic stroke: organizing effective and efficient daily care in The Netherlands]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Expertise on endometriosis]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Cataract surgery" -Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Surgery for varices" - Rapid report]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2006     Andalusian Health Technology Assessment Area (AETSA) [Expulsion stage of delivery: comparison of upright versus lying down positions for childbirth, through maternal and foetal outcomes]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2012     Andalusian Health Technology Assessment Area (AETSA) [Extended neonatal screening for lysosomal diseases by mass spectrometry]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [External evaluation of cancer care organization and delivery: review of experiences relevant to the cancer team evaluation and designation process in Québec]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [External evaluation of DACEHTA]
2007     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [External manual. Part 1]
2008     Basque Office for Health Technology Assessment (OSTEBA) [External review and validation of methodological instruments for the critical reading and summary of scientific evidence]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal liver support of liver failure by means of Prometheus system]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Extracorporeal photopheresis: main indications and implementation parameters]
2009     Committee for New Health Technology Assessment (CNHTA) [Extracorporeal photopheresis]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extracorporeal shock wave therapy (ESWT) for heel pain]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Extracorporeal shock wave therapy for orthopaedic indications]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal shock wave therapy in musculoskeletal disorders]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shock-wave treatment in orthopedics and rehabilitation. Update]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracranial stereotactic body radiotherapy in oligometastasis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2009     Committee for New Health Technology Assessment (CNHTA) [Extremely low temperature cool chamber]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2008     Committee for New Health Technology Assessment (CNHTA) [Eyeball brachytherapy]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for hypercholesterolaemia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for the prevention of cardiovascular events - Rapid report]
2009     Committee for New Health Technology Assessment (CNHTA) [F12 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [F7 gene, mutation[sequencing]]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Facility planning and infection prevention: sanitary facilities in specialized care rooms and cubicles]
2008     Committee for New Health Technology Assessment (CNHTA) [Facioscapulohumeral muscular dystrophy, D4Z4 analysis, PFGE/Southern Blot]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fact sheet: Screening for gestational diabetes - rapid report]
2017     Andalusian Health Technology Assessment Area (AETSA) [Faecal microbiota transplant for recurrent clostridium difficile infection. Up-date]
2011     Health Council of the Netherlands Gezondheidsraad (GR) [Fair compensation. Consideration of a proposal to give live kidney donors priority for transplants]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Fall-safe assist. Portable device for falls prevention]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Falling in line with the guidelines. Development and pilot testing of an implementation strategy to increase physiotherapists' adherence to evidence-based guidelines for patients with low back pain; a planned, systematic, and theory-based approach]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Falls in patients living in health care facilities (short- and long-term care)]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2006     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Familial hypercholesterolemia: evaluation of genetic screening by DNA microarrays]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]